http://flandersbio.be/news/ en info@flandersbio.be Copyright 2012 2012-05-17T06:51:46+00:00 http://flandersbio.be/news/ablynx-announces-q1-2012-business-update/ Ablynx [Euronext Brussels: ABLX], the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies® for the treatment of serious life-threatening diseases, today announced its business update for the three-month period ending 31st March 2012. 2012-05-17T06:51:46+00:00 http://flandersbio.be/news/christine-van-broeckhoven-given-prestigious-metlife-award-for-medical-research-worth-250000/ On Tuesday, May 15, in New York, the MetLife Foundation handed its annual Award for Medical Research to Christine Van Broeckhoven, of VIB and Universiteit Antwerpen, for her pioneering research on Alzheimer's disease and related disorders. This prestigious scientific award is given to outstanding scientific researchers. The substantial amount attached to the award is meant to give researchers the chance and free rein to develop new research ideas in the fight against dementia. 2012-05-16T11:18:13+00:00 http://flandersbio.be/news/durfkapitaalpoot-kbc-keert-overtollige-cash-uit-aan-moederbedrijf/ 2012-05-16T11:17:06+00:00 http://flandersbio.be/news/devgen-nv-business-update/ Devgen nv (Euronext Brussels: DEVG), an agro-biotech company that shapes the field of hybrid rice in India and Southeast Asia and innovates in crop protection technologies, today issued a business update and its three-month financial results ending 31 March 2012. 2012-05-16T10:58:44+00:00 http://flandersbio.be/news/mdxhealth-provides-first-quarter-2012-business-update/ MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today issued its business update for the quarter ended March 31, 2012. 2012-05-16T06:25:12+00:00 http://flandersbio.be/news/mdxhealth-launches-confirmmdx-for-prostate-cancer/ MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced the launch of ConfirmMDx™ for Prostate Cancer, a novel test that helps urologists distinguish patients who have a true-negative prostate biopsy from those who may have occult cancer. Testing will be performed in MDxHealth's state-of-the-art Irvine-based CLIA laboratory for physicians submitting prostate tissue samples directly or via its exclusive co-marketing partner PLUS Diagnostics. 2012-05-15T15:45:37+00:00 http://flandersbio.be/news/cambridge-healthtech-associates-announces-argen-x-as-inaugural-signature-award-winner-/ Cambridge Healthtech Associates™ (CHA™) today announced that arGEN-X is the winner of its inaugural Signature Award™. 2012-05-15T06:32:20+00:00 http://flandersbio.be/news/tigenix-reports-business-financial-results-for-the-first-quarter-2012-/ TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today gave a business update and announced the financial results for the first quarter ending March 31, 2012. 2012-05-15T06:15:05+00:00 http://flandersbio.be/news/100-miljoen-voor-uw-goede-doelen-de-tussenstand/ 2012-05-14T19:26:26+00:00 http://flandersbio.be/news/promethera-biosciences-treats-first-patients-with-promethera-hepastem/ Promethera Biosciences, a Belgian biotechnology Company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, today announces it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology. These patients were treated and are followed at the Cliniques Universitaires Saint-Luc (Brussels, Belgium). 2012-05-14T10:20:53+00:00